Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – What’s Next?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up before the market opened on Friday . The stock had previously closed at $13.43, but opened at $14.21. Astellas Pharma shares last traded at $14.1385, with a volume of 12,726 shares traded.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday. Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Finally, Smbc Nikko Sec. raised Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Astellas Pharma currently has a consensus rating of “Hold”.

Astellas Pharma Trading Up 5.7%

The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. The firm has a market cap of $25.68 billion, a price-to-earnings ratio of 13.21 and a beta of 0.08. The company has a 50-day moving average price of $15.29 and a 200 day moving average price of $14.51.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.14. The firm had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%. As a group, research analysts anticipate that Astellas Pharma Inc. will post 1.29 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).